Evidence map›Paper›PMID 41986608›Full record

ArticleNPJ digital medicine2026

An agentic AI system for automated pharmacogenomic recommendation generation.

Mike Zack, Anton Savinkov, Danil Stupichev, Alex Moore, David Sokolov, Igor Trifonov, Anastasia Yankovskiy, Kirill Reshetnikov, Nurkyz Ydyrysova, Allan Gobbs

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mike ZackPGxAI Inc., Palo Alto, CA, USA. mz@pgx.ai.
Anton SavinkovPGxAI Inc., Palo Alto, CA, USA.
Danil StupichevPGxAI Inc., Palo Alto, CA, USA.
Alex MoorePGxAI Inc., Palo Alto, CA, USA.
David SokolovPGxAI Inc., Palo Alto, CA, USA.
Igor TrifonovPGxAI Inc., Palo Alto, CA, USA.
Anastasia YankovskiyPGxAI Inc., Palo Alto, CA, USA.
Kirill ReshetnikovPGxAI Inc., Palo Alto, CA, USA.
Nurkyz YdyrysovaPGxAI Inc., Palo Alto, CA, USA.
Allan GobbsPGxAI Inc., Palo Alto, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacogenomic guidelines are essential for tailoring drug therapy to individual genetic profiles, but current curation workflows are manual, resource‑intensive, time‑bound, and limited in coverage. We introduce an agentic AI system for automated, scalable generation of CPIC-style recommendations using large language models (LLMs) guided by structured evidence. Our modular pipeline retrieves and processes full-text biomedical literature and FDA drug labels, extracts clinically relevant entities with high accuracy (91.9% across 22 articles), aggregates findings across studies, and generates phenotype-specific dosing recommendations for gene-drug pairs. In expert evaluations of 24 random recommendations, our system significantly outperformed leading LLM baselines (GPT-5, Claude, Grok) in clinical clarity and guideline concordance. These results demonstrate the feasibility of using evidence-grounded, agentic AI for end-to-end pharmacogenomic evidence synthesis, offering a path toward broader population coverage, faster updates, and more consistent and explainable decision support.

Identifiers

PMID41986608
PMCPMC13369662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.